Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | CITYSCAPE: tiragolumab in NSCLC

Melissa Johnson • 27 May 2020
ASCO 2020
Lung Cancer Non-Small Cell Lung Cancer Tiragolumab
CITYSCAPE

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the phase II CITYSCAPE study (NCT03563716) of the anti-TIGIT antibody tiragolumab plus atezolizumab versus placebo plus atezolizumab as first-line treatment in patients with PD-L1-selected NSCLC. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Melissa Johnson

1:49
ADCs for lung cancer
Melissa Johnson • 27 Feb 2023
1:30
Cellular therapies for NSCLC
Melissa Johnson • 27 Feb 2023
3:46
Targeting IL-2 in advanced NSCLC
Melissa Johnson • 27 Feb 2023
2:42
CodeBreaK 200: sotorasib versus docetaxel in pretreated KRAS G12C-mutant NSCLC
Melissa Johnson • 15 Sep 2022

Related Videos

1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
0:45
Assessing treatment options for lung cancer with interstitial lung disease
Matthew Hatton • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals